The US Food and Drug Administration (FDA) has approved VIZZ, a breakthrough eye drop for adults with presbyopia (farsightedness from aging). Unlike existing options, it can sharpen near vision for up to 10 hours with a lower profile of side effects, offering a new path for people who struggle with age-related near-vision blur. The drug is expected to be broadly available across the US by late 2025.
1. The First FDA-Approved Aceclidine-Based Presbyopia Eye Drop
In 2025, the FDA formally approved VIZZ for commercialization as a new prescription treatment for adults with presbyopia. Presbyopia is an inevitable change of aging where close objects become blurry; in the US alone, more than 100 million adults are estimated to be affected.
VIZZ was developed by LENZ Therapeutics, and its active ingredient is aceclidine. Users take it once daily, and it can improve near vision for up to 10 hours.
"For LENZ, VIZZ's approval is a defining milestone and, for the 128 million Americans with presbyopia, it introduces a genuinely new treatment option."
— Eef Schimmelpennink, CEO, LENZ Therapeutics
2. How VIZZ Works and Why It Is Different
VIZZ works by gently constricting the pupil, creating a pinhole effect similar to narrowing a camera aperture. In practice, aceclidine in the drop selectively reduces pupil size while largely sparing accommodation muscles, so users can see near objects more clearly without a major shift in distant vision.
"Unlike older presbyopia drops, VIZZ is designed to be pupil-selective and avoids major stimulation of the accommodation muscles, which helps preserve distance vision."
Compared with traditional drops like Vuity (pilocarpine-based), where side effects may include brow pain or, rarely, visual disturbances, VIZZ is positioned as a more pupil-selective, accommodation-sparing approach focused on near-vision quality.
3. Clinical Data and Safety
The approval is based on three phase 2 clinical trials with randomized, double-blind, controlled design. Across hundreds of participants and over 30,000 administered doses, no serious treatment-emergent adverse events were reported.
"FDA approval reflects the effort and discipline of our trial participants and investigators."
— Eef Schimmelpennink, CEO, LENZ Therapeutics
The combination of strong tolerability, quick onset, and a single daily dose with near-on demand effect lasting up to 10 hours is a key part of its differentiation.
4. Expectations from Patients and Ophthalmologists
Presbyopia is common for adults over 45, and many people find near-vision blur increasingly disruptive to daily life. Until now, many have relied on reading glasses and progressive lenses.
"This is a meaningful inflection for people who gradually lose near vision as they age," said Marc Bloomenstein, a trial investigator at Schwartz Laser Eye Care Center in Scottsdale. "Ophthalmologists should soon be able to offer patients a practical, on-demand treatment option."
Many observers expect VIZZ to become a meaningful new benchmark if uptake is strong after launch.
5. Market Timeline and Remaining Questions
LENZ Therapeutics has said it plans broad US availability in Q4 2025 (Oct-Dec). Because VIZZ is the first and currently the only FDA-approved aceclidine-based presbyopia drop, its launch is significant for a very large patient population.
"With fast onset and durable effect, this appears to be an optimized option for many presbyopic patients. It is also the first clinically supported, pupil-selective, accommodation-sparing option in this class."
— Eef Schimmelpennink
Peer-reviewed publication is still pending, which is typical in this space; additional manuscripts are expected as the company and clinical community continue to share full trial data.
Conclusion
VIZZ represents a practical shift: improving near vision in presbyopic adults without forcing patients into invasive interventions. Its launch in late 2025 could provide many people with more freedom in day-to-day tasks requiring sustained near focus. 👀✨